Neurocrine Biosciences (NBIX) Competitors $132.14 +0.50 (+0.38%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$132.17 +0.03 (+0.02%) As of 07/25/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NBIX vs. ALNY, BIIB, INCY, UTHR, EXEL, BMRN, EXAS, HALO, MDGL, and RGENShould you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. Neurocrine Biosciences vs. Its Competitors Alnylam Pharmaceuticals Biogen Incyte United Therapeutics Exelixis BioMarin Pharmaceutical Exact Sciences Halozyme Therapeutics Madrigal Pharmaceuticals Repligen Neurocrine Biosciences (NASDAQ:NBIX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation. Do insiders & institutionals have more ownership in NBIX or ALNY? 92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 4.8% of Neurocrine Biosciences shares are owned by company insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has higher valuation and earnings, NBIX or ALNY? Neurocrine Biosciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurocrine Biosciences$2.36B5.55$341.30M$2.9544.79Alnylam Pharmaceuticals$2.25B19.07-$278.16M-$2.09-157.33 Does the media favor NBIX or ALNY? In the previous week, Alnylam Pharmaceuticals had 5 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 22 mentions for Alnylam Pharmaceuticals and 17 mentions for Neurocrine Biosciences. Alnylam Pharmaceuticals' average media sentiment score of 1.03 beat Neurocrine Biosciences' score of 0.86 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 7 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 13 Very Positive mention(s) 5 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, NBIX or ALNY? Neurocrine Biosciences has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Do analysts prefer NBIX or ALNY? Neurocrine Biosciences presently has a consensus target price of $163.87, indicating a potential upside of 24.01%. Alnylam Pharmaceuticals has a consensus target price of $347.75, indicating a potential upside of 5.76%. Given Neurocrine Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Neurocrine Biosciences is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurocrine Biosciences 0 Sell rating(s) 3 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.88Alnylam Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 22 Buy rating(s) 0 Strong Buy rating(s) 2.81 Is NBIX or ALNY more profitable? Neurocrine Biosciences has a net margin of 12.68% compared to Alnylam Pharmaceuticals' net margin of -11.49%. Neurocrine Biosciences' return on equity of 11.81% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Neurocrine Biosciences12.68% 11.81% 8.59% Alnylam Pharmaceuticals -11.49%-510.31%-6.48% SummaryNeurocrine Biosciences beats Alnylam Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBIX vs. The Competition Export to ExcelMetricNeurocrine BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.03B$2.49B$5.70B$9.50BDividend YieldN/A1.65%4.58%4.00%P/E Ratio44.799.1828.3920.08Price / Sales5.55609.56431.7689.31Price / Cash38.95165.2136.2258.56Price / Book5.175.168.675.88Net Income$341.30M$30.99M$3.25B$258.89M7 Day Performance0.09%7.73%4.25%3.71%1 Month Performance4.29%16.27%10.51%11.72%1 Year Performance-9.99%-1.88%35.68%18.01% Neurocrine Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBIXNeurocrine Biosciences4.4342 of 5 stars$132.14+0.4%$163.87+24.0%-9.6%$13.03B$2.36B44.791,800Upcoming EarningsAnalyst ForecastALNYAlnylam Pharmaceuticals4.0718 of 5 stars$315.75+0.3%$345.70+9.5%+38.2%$41.17B$2.25B-151.082,230News CoveragePositive NewsUpcoming EarningsBIIBBiogen4.8068 of 5 stars$133.11-0.8%$188.48+41.6%-42.2%$19.50B$9.68B13.147,605Upcoming EarningsAnalyst RevisionINCYIncyte4.6257 of 5 stars$69.98+2.0%$74.47+6.4%+2.4%$13.55B$4.24B218.692,617Positive NewsUpcoming EarningsInsider TradeUTHRUnited Therapeutics4.9909 of 5 stars$297.68+0.7%$383.08+28.7%-9.5%$13.43B$2.88B11.881,305Trending NewsUpcoming EarningsInsider TradeAnalyst RevisionEXELExelixis4.778 of 5 stars$45.58+1.6%$45.22-0.8%+98.6%$12.43B$2.17B20.721,147News CoveragePositive NewsUpcoming EarningsAnalyst ForecastBMRNBioMarin Pharmaceutical4.9842 of 5 stars$58.23+0.2%$93.78+61.1%-31.1%$11.17B$2.85B21.653,040Analyst ForecastEXASExact Sciences4.7433 of 5 stars$54.30+4.6%$70.50+29.8%+0.3%$10.24B$2.76B-9.857,000News CoveragePositive NewsHALOHalozyme Therapeutics4.8505 of 5 stars$57.65+0.9%$62.50+8.4%+4.1%$7.10B$1.02B15.33390Positive NewsMDGLMadrigal Pharmaceuticals4.313 of 5 stars$319.87+1.4%$420.63+31.5%+5.3%$7.10B$180.13M-17.7290News CoverageInsider TradeRGENRepligen4.6378 of 5 stars$121.33-6.8%$170.75+40.7%-8.0%$6.82B$650.43M-269.621,778Upcoming EarningsAnalyst Upgrade Related Companies and Tools Related Companies Alnylam Pharmaceuticals Competitors Biogen Competitors Incyte Competitors United Therapeutics Competitors Exelixis Competitors BioMarin Pharmaceutical Competitors Exact Sciences Competitors Halozyme Therapeutics Competitors Madrigal Pharmaceuticals Competitors Repligen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBIX) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
